Niagen Bioscience, Inc. (NASDAQ: NAGE), a leader in NAD+ science and healthy aging, on Monday announced the debut of its Tru Niagen supplement and Niagen IV therapy at Equinox Hotel New York, marking the company's first hotel collaboration.
Tru Niagen, now available in all guest suites, and Niagen IV, offered through NutriDrip at The Spa by Equinox Hotel New York, aim to enhance cellular energy production and DNA repair. Both products feature Niagen - a patented nicotinamide riboside (NR) - clinically proven to boost NAD+ levels, a key coenzyme that declines with age and stress.
Tru Niagen is supported by over 35 clinical studies and 400 peer-reviewed publications, and is third-party certified, including NSF Certified for Sport status for selected products. Niagen IV, designed as a more tolerable and efficient alternative to standard NAD+ IV therapy, demonstrated a 75% shorter infusion time and a 20% increase in NAD+ levels three hours post-infusion in clinical testing.
Niagen Bioscience, formerly ChromaDex Corp, is expanding its presence in the premium wellness market by aligning with Equinox's luxury, performance-driven hospitality model. Pharmaceutical-grade Niagen IV is available only via prescription at licensed clinics and is compounded by FDA-registered 503B outsourcing facilities.
Sanofi receives US fast track designation for gene therapy targeting geographic atrophy
Currax expands access to Contrave obesity treatment
Varian launches IntelliBlate in Europe, expanding image-guided microwave ablation for cancer care
Biophytis partners with Lynx Analytics to advance AI-driven drug discovery for sarcopenia
Niagen Bioscience introduces Tru Niagen and Niagen IV at Equinox Hotel New York
Gilead showcases efficacy of twice-yearly lenacapavir for HIV prevention at IAS 2025
GSK announces submission of RSV vaccine Arexvy for FDA review
Imugene announces Azer-cel Phase 1b clinical trial data
FDA approves Merck Animal Health's once-yearly flea and tick treatment for dogs